相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
George D. Demetri et al.
CLINICAL CANCER RESEARCH (2022)
Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.
David S. Hong et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults
D. Gwyn Bebb et al.
CURRENT ONCOLOGY (2021)
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Ezra Y. Rosen et al.
CLINICAL CANCER RESEARCH (2020)
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong et al.
LANCET ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Systemic therapy for metastatic salivary gland tumors-challenges and novel concepts
Christoph Minichsdorfer
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2020)
Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy
Susan J. Hsiao et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2019)
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
C. Marchio et al.
ANNALS OF ONCOLOGY (2019)
Identifying patients with NTRK fusion cancer
J. P. Solomon et al.
ANNALS OF ONCOLOGY (2019)
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
A. Amatu et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma Findings of the Phase 1b KEYNOTE-028 Study
Roger B. Cohen et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
Molecular Profiling of Mammary Analog Secretory Carcinoma Revealed a Subset of Tumors Harboring a Novel ETV6-RET Translocation: Report of 10 Cases
Alena Skalova et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon et al.
CANCER DISCOVERY (2017)
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions
Jaclyn F. Hechtman et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
A. Drilon et al.
ANNALS OF ONCOLOGY (2016)
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor
Christian Rolfo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Mammary analogue secretory carcinoma of salivary glands: a new entity associated with ETV6 gene rearrangement
Hanna Majewska et al.
VIRCHOWS ARCHIV (2015)
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Aria Vaishnavi et al.
CANCER DISCOVERY (2015)
Mammary Analogue Secretory Carcinoma of Salivary Glands, Containing the ETV6-NTRK3 Fusion Gene: A Hitherto Undescribed Salivary Gland Tumor Entity
Alena Skalova et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Systemic therapy in the palliative management of advanced salivary gland cancers
Scott A. Laurie et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
分享论文
